Abstract
A mutation of the p16INK4a-binding domain of the cyclin dependent kinase 4 (CDK4) gene, R24C, has been reported in some cases of melanoma. This mutation prevented binding of the CDK4 inhibitor p16INK4a to CDK4. To determine the relevance of the mutation, we performed polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) analysis in diverse types of human leukemias and solid tumors. No mobility shifts indicating sequence alterations were observed in 273 tumors and 49 cell lines from diverse kinds of tumors. These results suggest that in contrast to melanoma, in many other types of human neoplasms the mutation of the CDK4 gene is very rare. To better understand these findings, we randomly mutagenized the CDK4 gene and used the yeast two-hybrid method to screen for CDK4 mutants that had lost the ability to bind to p16INK4a. Sequence analysis and in vitro kinase assays showed that most of the mutations that disrupted interactions with p16INK4a also knocked out the activity of CDK4.This result may explain the rareness of CDK4 mutations in human tumors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer.Blood. 1995;86:841–854.
Wolfel T, Hauer M, Schneider J, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.Science. 1995;269:1281–1284.
Zuo L, Weger J, Yang Q, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma.Nature Genet. 1996;12:97–99.
Fitzgerald MG, Harkin DP, Silva-Arrieta S, et al. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.Proc Natl Acad Sci U S A. 1996;93:8541–8545.
Qari MH, Khalil SH, Kambouris M, Meyer BF. Mutation of p16, p21 or cyclin dependent kinase 4 is rare in acute lymphoblastic leukaemia.Br J Haematol. 1998;103:467–472.
Einsiedel HG, Taube T, Beyermann B, et al. Absence of mutations in the CDKN2 binding site of CDK4 in childhood acute lymphoblastic leukemia.Leuk Lymphoma. 2001;40:413–417.
Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.Genomics. 1989;5:874–879.
Yang R, Serrano M, Slater J, Leung E, Koeffler HP. Analysis of p16INK4A and its interaction with CDK4.Biochem Biophy Res Commun. 1997;218:254–259.
Serrano M, Hannon GJ, Beach D. A new regulatory motif in cellcycle control causing specific inhibition of cyclin D/CDK4.Nature. 1993;366:704–707.
De Bondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, Kim S. Crystal structure of cyclin-dependent kinase 2.Nature. 1993; 363:595–602.
Weinberg RA. Tumor suppressor genes.Science. 1991;254:1138–11466.
Guldberg P, Kirkin AF, Gronbaek K, thor Straten P, Ahrenkiel V, Zeuthen J. Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: a novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma.Int J Cancer. 1997;72:780–783.
Coleman KG, Wautlet BS, Morrissey D, et al. Identification of CDK4 sequences involved in cyclin D1 and p16 binding.J Biol Chem. 1997;272:18869–18874
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Mori, N., Yang, R., Kawamata, N. et al. Absence of R24C Mutation of the CDK4 Gene in Leukemias and Solid Tumors. Int J Hematol 77, 259–262 (2003). https://doi.org/10.1007/BF02983783
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02983783